MedTrace Logo

Blood for Immune Response to Provenge® in HRPC

NCT01274572 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2015-04-07

No results posted yet for this study

Summary

This study is being conducted to assess and monitor immune response in patients with minimally symptomatic or asymptomatic hormone refractory prostate cancer who will be receiving Provenge® (Sipuleucel-T) therapy as part of their standard of care treatment regimen.

Conditions

Sponsors & Collaborators

  • Mary Crowley Medical Research Center

    lead OTHER

Principal Investigators

  • John Nemunaitis, MD · Mary Crowley Cancer Research Centers

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-01-31
Completion
2011-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01274572 on ClinicalTrials.gov